摘要
目的研究参苓白术散治疗腹泻型肠易激综合征(IBS-D)的临床疗效及其对肠黏膜相关蛋白的作用。方法选择福建中医药大学附属人民医院就诊的106例IBS-D(脾虚湿盛型)患者(2022年1月至2024年1月),按随机数字表法分成对照组(双歧杆菌乳杆菌三联活菌片治疗)和治疗组(参苓白术散治疗),各53例。两组均治疗4周。观察两组的临床疗效、中医证候积分变化、不良反应发生率及结肠黏膜中Toll样受体4(TLR4)、髓样分化因子88(MyD88)以及核因子κB(NF-κB)蛋白的表达量。结果治疗组的总有效率相较于对照组更高(P<0.05)。治疗后,治疗组的积分下降,降幅大于对照组,且不良反应的总发生率低于对照组(P<0.05)。治疗后治疗组中各项蛋白的阳性表达率均高于对照组(P<0.05)。结论参苓白术散对IBS-D(脾虚湿盛型)患者的疗效确切且安全,并影响肠黏膜中TLR4、MyD88、NF-κB蛋白水平。
Objective To study the clinical efficacy of Shenling Baizhu Powder in the treatment of diarrhea-predominant irritable bowel syndrome(IBS-D)and its effect on intestinal mucosa-related proteins.Methods From January 2022 to January 2024,106 patients diagnosed with IBS-D(characterized by spleen-deficiency and dampexcess syndrome)and receiving medical care at the People’s Hospital Affiliated to Fujian University of Traditional Chinese Medicine were randomly assigned to two groups via the random number table method.One group,the control group,was administered Bifidobacterium Lactobacillus Triple Viable Tablets,while the other,the treatment group,received Shenling Baizhu San.The treatment duration for both groups was 4 weeks.During the study,we monitored and compared the clinical efficacy,alterations in traditional Chinese medicine syndrome scores,the frequency of adverse reactions,as well as the expression levels of Toll-Like receptor 4(TLR4),myeloid differentiation factor 88(MyD88),and nuclear factor-κB(NF-κB)proteins in the colonic mucosa between the two groups.Results Compared with the control group,the treatment group exhibited a higher total effective rate.Once the treatment concluded,the reduction in scores within the treatment group proved to be substantially larger than that in the control group.Meanwhile,the overall occurrence rate of adverse reactions in the treatment group was notably lower than in the control group,and these differences reached statistical significance(P<0.05).Moreover,following the treatment,the treatment group exhibited significantly higher positive expression rates of various proteins compared to the control group(P<0.05).Conclusions Shenling Baizhu San is effective and safe in the treatment of IBS-D(spleen deficiency with excessive dampness),and affects the expression of TLR4,MyD88 and NF-κB in intestinal mucosa.
作者
陈静
杨陈婷
唐杜鹏
CHEN Jing;YANG Chenting;TANG Dupeng(Department of Gastroenterology,the Affiliated People’s Hospital of Fujian University of Traditional Chinese Medicine,Fuzhou,Fujian 350004,China)
出处
《中国医药指南》
2025年第32期166-169,共4页
Guide of China Medicine
基金
福建省中青年教师教育科研项目(JAT210194)
2023年福建省“创双高”临床重点专科(脾胃)项目(闽卫医政函〔2023〕1163号)。
关键词
腹泻型肠易激综合征
参苓白术散
肠黏膜相关蛋白
Diarrhea-Predominant irritable bowel syndrome
Shenling Baizhu San
Intestinal mucosa-related proteins
